Prices Soar for New Hepatitis C Drug
Medicare’s spending on drugs to treat hepatitis C soared more than 15 fold from 2013 to 2014 as new breakthroughs came to the market, accoridng to a new investigation by ProPublica with The Washington Post. Sen. Bernie Sanders has been a critic of the high price of the new drugs. “The cost of Sovaldi is not only an economic issue in terms of the impact of the cost of this drug on the VA, on Medicaid, on Medicare, it is a moral issue, and that is how many people in this country will suffer, how many will die very painful deaths because of the excessive costs of this particular product," Sanders said.
